Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Research and development	$ 248,626	$ 132,944	$ 99,591
Research and development related success payments and contingent consideration	57,873	124,935	19,784
General and administrative	50,410	28,270	21,777
Total operating expenses	356,909	286,149	141,152
Loss from operations	(356,909)	(286,149)	(141,152)
Interest income, net	676	747	2,856
Other income (expense), net	305	97	(29)
Loss before income taxes	(355,928)	(285,305)	(138,325)
Benefit from income taxes			7,547
Net loss	$ (355,928)	$ (285,305)	$ (130,778)
Net loss per common share - basic and diluted	$ (2.14)	$ (21.92)	$ (26.68)
Weighted-average number of common shares - basic and diluted	166,433	13,014	4,903